Drug intelligence / Profile preview

lambda interferon adenovirus

Development stage
Preclinical
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration
Intravenous, Intratumoral, Intranasal, Local Injection
01

Overview

Lambda interferon adenovirus refers to a *gene therapy modality* using an adenoviral vector to express human interferon lambda (IFN-λ1 or IFN-λ2) in target tissues or cells. Lambda interferon (also called IFN-λ or type III interferon) is a cytokine with potent, epithelial-specific antiviral and immunomodulatory activity. The adenoviral vector delivers the IFN-λ gene to cells, leading to local production of interferon lambda protein. Mechanistically, IFN-λ binds to the interferon lambda receptor (IFNLR1/IL-10R2), activating the JAK/STAT pathway, upregulating antiviral and pro-apoptotic genes, and modulating immune responses with focus on epithelial barriers such as respiratory, hepatic, and gastrointestinal mucosa. In experimental cancer models, lambda interferon adenovirus induces tumor cell apoptosis and suppresses proliferation via STAT1/2/3 activation and the Bcl-2/Bax-caspase cascade[7]. In respiratory viral and cancer contexts, it enhances localized antiviral immunity while minimizing systemic inflammation.

Other names
adenovirus expressing interferon lambdaadenoviral interferon lambdaadenovirus vector IFN-lambda
02

Targets

IFNLR (Interferon Lambda Receptor)IL10RA (Interleukin-10 Receptor)STAT1 (Signal transducer and activator of transcription protein 1)STAT2STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on lambda interferon adenovirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lambda interferon adenovirus.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call